Wolverine peptide stack · Updated October 17, 2026

What is the wolverine peptide stack?

Short answer

The wolverine stack is two lab-made peptides, BPC-157 and TB-500, used together in hopes of faster recovery from muscle, tendon and other tissue injuries.^[1]^[2] It is not FDA-approved, and most of the evidence comes from animal and lab studies, with only a few tiny human reports.^[1]^[2]^[3] Both peptides are banned in sport.^[15]

Start your assessment

Your card is only held at checkout. You’re charged only if a provider prescribes.

Licensed provider review
Online, no office visit
Every fact cited to its source

Quick fit check

Tick anything that applies to you. Nothing you tick is saved or sent anywhere.

You compete in a drug-tested sport
WADA bans BPC-157 and TB-500 at all times, and athletes are strictly liable for what is in their systems.^[15]^[17] USADA says a therapeutic use exemption for BPC-157 is unlikely to be approved.^[16]
You want an FDA-approved treatment
The stack is not FDA-approved, and USADA says BPC-157 is not approved for human use by FDA or any other health authority. A provider will weigh this.^[1]^[16]
You have a history of cancer or precancerous cells
Some peptides promote new blood vessel growth, which could in theory feed a tumor, and no human safety trials have tested this. A provider will weigh this history.^[1]
You have reacted to a peptide injection before
FDA has flagged a risk that injected forms of both peptides could trigger immune reactions. A provider will weigh any past reaction.^[6]^[7]
You were planning to buy peptides sold online as research chemicals
Products sold as research chemicals come with no guarantee of what is in the vial.^[11] FDA has said “research purpose only” labels do not stop such products from being unapproved drugs.^[14]

How to get started

Answer health questions
An online assessment about your health, history and goals.
A licensed provider reviews it
They decide whether a prescription is safe and appropriate for you.
If prescribed, it ships to you
Your card is only held at checkout. You’re charged only if a provider prescribes.

Not ready yet?

Get occasional updates on the wolverine stack: new research, safety news and rule changes.

Used only to send these updates. Unsubscribe anytime.

Key facts

What's in it: BPC-157, a 15 amino acid peptide, plus TB-500, a 7 amino acid fragment of thymosin beta-4.^[6]^[7]^[8]
What people use it for: Hoped-for faster healing of muscle, tendon and other soft-tissue injuries. These are claims, not proven benefits.^[1]^[2]
FDA status: Not FDA-approved. FDA advisers voted in July 2026 to recommend allowing pharmacy compounding, but the vote is non-binding.^[1]^[11]
Evidence base: Mostly animal and lab studies. A 2026 review found 3 small human studies of BPC-157 with 30 people in total, all of poor quality.^[2]^[3]
In sport: Banned at all times by the World Anti-Doping Agency: BPC-157 under S0 and TB-500 under S2.^[15]
How it is usually taken: Usually injected under the skin or into a muscle, often from products sold for “research purposes.”^[1]

Regulatory timeline

Date	What happened
June 12, 2023	An FDA warning letter called products labeled BPC-157 and TB-500 unapproved new drugs, despite “research purpose only” labels.^[14]
January 1, 2026	The 2026 WADA Prohibited List takes effect, naming BPC-157 under S0 and TB-500 under S2.^[15]
July 23, 2026	FDA’s compounding advisory committee votes 8 to 6, with 1 abstention, to recommend adding BPC-157, TB-500 and KPV to the 503A bulks list.^[12]
October 14, 2026	White House regulatory reviewers receive an FDA interim access policy for compounding certain peptides. Its text and covered peptides are not public.^[13]
January 1, 2027	The 2027 WADA Prohibited List takes effect. BPC-157 and TB-500 remain prohibited.^[17]

What's in it

BPC-157: A synthetic peptide made to match part of a “body protection compound” first found in human stomach juice.^[16] FDA describes it as a peptide of 15 amino acids.^[6]
TB-500: A short synthetic peptide of 7 amino acids that FDA lists as a fragment of thymosin beta-4.^[7]^[8] FDA notes that “TB-500” is a common name, not an official drug name, so a product may not contain the substance a prescriber intended.^[7]
The “stack”: Stacking means using more than one peptide at the same time.^[1] Human data on this pair is limited to a 2021 chart review in which 4 people got knee injections of BPC-157 combined with thymosin beta-4, and 3 reported improvement.^[2]^[4]

What the evidence shows

Animal and lab studies: A 2025 systematic review found 36 studies of BPC-157 in sports medicine: 35 preclinical and 1 clinical.^[3] In animal models, BPC-157 improved healing of muscle, tendon, ligament and bone injuries.^[3] A 2026 review of sports medicine peptides, including BPC-157 and TB-500, found that many unapproved peptides do well in animal models but rigorous human safety data are scarce.^[5]
Human studies of BPC-157: A 2026 systematic review found 3 human studies with 30 people in total: a knee pain chart review (16 people), a bladder pain pilot (12) and an intravenous safety pilot (2).^[2] All 3 were judged poor quality, and the review rated the overall certainty of evidence as very low.^[2]
Human studies of TB-500: FDA found no clinical studies or human exposure data for TB-500 by any route.^[7]
FDA’s own review: In its July 2026 briefing documents, FDA staff found a lack of evidence of effectiveness and proposed not adding either peptide to the compounding list.^[6]^[7]

Legal and regulatory status

Not approved: The stack is not FDA-approved.^[1] USADA says BPC-157 is not approved for human clinical use by FDA or any other global health authority.^[16]
Compounding rules: Under section 503A, pharmacies may compound only with bulk substances that have a USP or NF monograph, are part of an FDA-approved drug, or appear on FDA’s 503A bulks list.^[9] As of August 2026, USADA said there was no legal basis to include BPC-157 in any compounded medication.^[16]
FDA safety list: FDA lists BPC-157 and TB-500 among substances that were previously in its “category 2” of potential significant safety risks and whose nominations were withdrawn.^[8]
July 2026 advisory vote: FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding both peptides to the 503A bulks list, against FDA staff’s recommendation.^[11]^[12] Advisory committee votes are non-binding, and FDA must still review the record and publish proposed rules before anything becomes official.^[10]^[11]
Pending interim policy: On October 14, 2026, White House regulatory reviewers received an FDA “Interim Access Policy for Compounding Using Certain Peptides,” listed as pending review.^[13] The public record does not disclose which peptides it covers or its conditions.^[13]
Selling as “research” chemicals: FDA has warned that “research purpose only” labels do not stop products from being treated as drugs for human use.^[14]

Risks and unknowns

Unknown safety in people: FDA says it lacks enough information to know whether BPC-157 or TB-500 would cause harm in humans.^[8]
Immune reactions: FDA is concerned that injected forms of both peptides could trigger immune reactions, partly because of clumping and peptide-related impurities.^[6]^[7]
Product quality: Many people buy these compounds online as unregulated “research chemicals,” with no doctor involved and no guarantee of what is in the vial.^[11] Injecting a product made in unverified conditions carries a risk of infection or contamination.^[1]
Reported side effects: Anecdotal reports include injection site irritation, stomach upset, tiredness and headaches.^[1] FDA’s adverse event database held three reports for injected BPC-157, including an injection site reaction, shortness of breath, and darkening of the skin and gums.^[6]
Animal safety signals: In 28-day studies, BPC-157 injected into muscle in rats and dogs was linked to changes in blood clotting tests and liver-related lab values.^[6]
Cancer question: Because some peptides work by promoting new blood vessel growth, they could in theory feed blood vessels to a tumor in someone with precancerous cells. No human safety trials have tested this.^[1]

Common questions

Does the wolverine stack work?

There is no good human evidence that it does, and a 2026 review rated the certainty of the human evidence as very low.^[2] Animal studies of BPC-157 look promising, but the few human studies are tiny and of poor quality, and FDA found no human data for TB-500.^[2]^[3]^[7]

Is the wolverine stack safe?

Its safety in people is unknown.^[8] FDA says it lacks enough information to know whether either peptide would cause harm in humans, and it has flagged risks such as immune reactions and impurities.^[6]^[7]^[8]

Is the wolverine stack legal?

It is not FDA-approved.^[1] FDA advisers voted in July 2026 to recommend letting compounding pharmacies use BPC-157 and TB-500, but the vote is non-binding.^[11]^[12] As of October 16, 2026, an FDA interim policy on compounding certain peptides was still under White House review, and state pharmacy rules also apply.^[13]

Is the wolverine stack banned in sports?

Yes. The 2026 WADA Prohibited List bans BPC-157 under S0 and thymosin beta-4 and its derivatives, such as TB-500, under S2, both at all times.^[15] Both remain prohibited on the 2027 list.^[17] USADA says a therapeutic use exemption for BPC-157 is unlikely to be approved.^[16]

Why is it called the wolverine stack?

The nickname refers to the Marvel character known for regenerative healing, based on the stack’s supposed regenerative effects.^[1]

How long does the wolverine stack take to work?

There is no reliable human data on timing.^[2]^[7] The few human studies of BPC-157 were small and had no control group, and FDA found no human studies of TB-500.^[2]^[7]

Talk to a provider about injury recovery

Complete an online health assessment. A licensed provider reviews it and decides whether this stack or another option is appropriate for you.